ClinicalTrials.gg
RecruitingNCT05660798SWITCHUpdated Dec 19, 2024

Effects of Switching From Cigarettes to Tobacco Heating System on Coronary Atherosclerosis Progression

An interventional study of heated tobacco - lifestyle intervention in Coronary Artery Disease, Coronary Atherosclerosis and Nicotine Dependence, sponsored by National Institute of Cardiology, Warsaw, Poland. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-19.

Sponsored by National Institute of Cardiology, Warsaw, Poland · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland — 5 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · National Institute of Cardiology, Warsaw, Poland.

Planned enrollment
4th of 12
180 · median 97
Started
2023
with 1 other
No phase
9 of 18
3 open now
Registered
12th of 18
by date

Among the 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is one of 9 with no phase, and was the 12th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland, or all of them as a file.
02

Study summary

Objective:

To evaluate the impact of heated versus combustion tobacco products on progression of atherosclerosis in patients with CAD unable(unwilling) to quit smoking.

Rationale:

Despite the efforts to curb smoking and full awareness of its deleterious health impact, smoking remains a significant contributor to morbidity and mortality. Some health impact of smoking may be improved by other forms of cigarettes than traditional combustion, especially for subjects unwilling or unable to stop smoking. As recently as 2020, one of heated tobacco products (HTP)(IQOS) was FDA Authorized as a 'Reduced Exposure' product. The available evidence to date allows to conclude that the IQOS system heats tobacco but does not burn it, which significantly reduces the production of harmful and potentially harmful chemicals. Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduced body's exposure to harmful or potentially harmful chemicals. There is also evidence indicating lower levels of inflammatory markers and improved vascular function associated with use of heated tobacco products. However, it is unknown whether the reduction in the exposure translates into potential reduction of harm within cardiovascular system, as compared to the traditional (combustion) cigarettes.

The evidence is of crucial importance for patients with cardiovascular diseases, medical community, and national health authorities planning evidence based policies regarding HTP/cigarettes.

Read the detailed description

Objective:

To evaluate the impact of heated versus combustion tobacco products on progression of atherosclerosis in patients with CAD unable(unwilling) to quit smoking.

Background Despite the efforts to curb smoking and full awareness of its deleterious health impact, smoking remains a significant contributor to morbidity and mortality. Some health impact of smoking may be improved by other forms of cigarettes than traditional combustion, especially for subjects unwilling or unable to stop smoking. As recently as 2020, one of heated tobacco products (HTP)(IQOS) was FDA Authorized as a 'Reduced Exposure' product. The available evidence to date allows to conclude that the IQOS system heats tobacco but does not burn it, which significantly reduces the production of harmful and potentially harmful chemicals. Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduced body's exposure to harmful or potentially harmful chemicals. There is also evidence indicating lower levels of inflammatory markers and improved vascular function associated with use of heated tobacco products. However, it is unknown whether the reduction in the exposure translates into potential reduction of harm within cardiovascular system, as compared to the traditional (combustion) cigarettes.

The evidence is of crucial importance for patients with cardiovascular diseases, medical community, and national health authorities planning evidence based policies regarding HTP/cigarettes.

Methods:

Prospective, single-centre, open-label, randomised study including 180 stable patients with coronary artery disease (CAD) as diagnosed on CCTA, without indications for invasive treatment, unable(unwilling) to quit smoking, randomised 1:1 to either heated (group H) or combustion (group C) tobacco products and followed for 18 months. The follow-up is accomplished with CCTA scan. The study clinical visits are planned at 1, 3, 6, 12, and 18 months.

The primary outcome is change in non calcified plaque volume at 18 months between H and C groups (intention to treat design).

03

Conditions studied

  • Coronary Artery Disease
  • Coronary Atherosclerosis
  • Nicotine Dependence
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged >18 years and \<75 years
  2. Subjects with stable chronic coronary syndrome defined as the presence of at least one coronary artery stenosis >=20% due to coronary plaque visible on coronary computed tomography angiography (CCTA), in an artery with a reference diameter > 2.0mm
  3. History of smoking pack-years ≥10 (Pack-years will be calculated by taking the average number of cigarettes smoked per day divided by 20 and multiplied by the number of years smoked), based on self-reporting
  4. Current smokers with a minimum of self-reported current smoking pattern of >10 cigarettes/day during the last 6 months prior to screening, smoking status will be verified based on a urinary cotinine test (cotinine ≥200 ng/mL)
  5. Patients that have been advised to quit smoking and informed of a smoking risk and cessation programs (per local SOC) and who are still not willing to set a quit date within the next 30 days at screening
  6. Stable treatment for coronary atherosclerosis according to the guidelines
  7. Have understood the study and have signed

Exclusion criteria

Exclusion Criteria:

  1. Any acute cardiovascular event (i.e. ACS, MI, Stroke, , Limb ischemia), unstable angina or revascularization within 30 days prior to screening
  2. Planned coronary intervention (PCI, CABG) at screening
  3. Previous CABG
  4. Preexisting heart failure with reduced (EF \<50%)
  5. Severe uncontrolled hypertension (at the discretion of investigator)
  6. Diabetes
  7. Subjects with documented genetic familial hypercholesterolemia
  8. Subjects have known serious infection or chronic inflammatory systemic disease (e.g. rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis)
  9. Subjects have a known non-cardiovascular disease that is associated with poor prognosis (e.g. cancer)
  10. Patient with currently active cancer or history of cancer within the last 5 years
  11. Subjects have or any other warnings listed in the local labeling for THS
  12. Subjects have hypersensitivity to imaging iodine contrast agents
  13. \<45 ml/min/1,73 m2
  14. Subjects who could not participate for any reason other than medical (e.g., psychological and/or social reason) per Investigator's judgment
  15. Subjects have any other clinical condition that would jeopardize the subject's safety while participating in this study, per Investigator's judgment
  16. Female subject is pregnant or breast-feeding, or planning to become pregnant during the study
  17. Subjects have previously participated in this study, or in an interventional study (drug or medical device) within 30 days of screening (participation in observational studies/registries allowed)
  18. Subjects have a close affiliation with the site: a close relative of the investigator, a person dependent on the investigational site (e.g. employee or student of the investigational site)
  19. Subjects are current or former employee of the tobacco industry or their first-degree relatives (parent, child, spouse)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • No intervention
    combustion tobacco
  • Experimental
    heated tobacco

    Behavioral: heated tobacco - lifestyle intervention

Interventions

  • Behavioralheated tobacco - lifestyle intervention

    Patients unable (unwilling) to stop smoking will be randomized to either combustion (C) or heated (H) tobacco groups.

06

What researchers measure

Primary outcomes

  1. Change in non calcified plaque volume between H and C groups ("intention to treat")

    CCTA based evaluation

    Time frame: 0-18 months

Secondary outcomes

  1. Change in total plaque volume

    CCTA based evaluation

    Time frame: 0-18 months

  2. Change in plaque volume components (low attenuation, fibrous-fatty, fibrous, non-calcified plaque, calcified plaque)

    CCTA based evaluation

    Time frame: 0-18 months

  3. Change in non calcified plaque volume between H and C groups ("as treated")

    CCTA based evaluation

    Time frame: 0-18 months

  4. Change in lipid metabolism

    Total cholesterol (TC) Triglycerides (TG) Lipoproteins: low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) Apolipoproteins: apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB) Lipoprotein(a) Lp(a)

    Time frame: 0-18 months

  5. Change in oxidative stress

    8-Epi prostaglandin F2 alpha (8 epi PGF2α) Myeloperoxidase (MPO)

    Time frame: 0-18 months

  6. Change in inflammation

    High-sensitivity C-reactive protein (hs CRP) White blood cell (WBC) counts Homocysteine Interleukins (IL-6) Fibrinogen

    Time frame: 0-18 months

  7. Change in platelet activation

    11-dehydro-thromboxane B2 (11 DTX B2) Plasminogen activator inhibitor-1 (PAI-1) Tissue plasminogen activator (t-PA) Platelet count Mean platelet volume (MPV)

    Time frame: 0-18 months

  8. Change in endothelial dysfunction

    P-selectin Metalloproteinase 9 (MMP-9)

    Time frame: 0-18 months

  9. Change in haemodynamic stress

    N-terminal pro b-type natriuretic peptide (NT-proBNP)

    Time frame: 0-18 months

  10. Change in myocardial injury

    high-sensitivity troponin T (hs-TnT)

    Time frame: 0-18 months

  11. Change in glycemia control

    Fasting Blood Glucose, HbA1c

    Time frame: 0-18 months

  12. Change in physical activity

    self reported, mobile device monitoring

    Time frame: 0-18 months

  13. Change in exposure to nicotine

    4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol , Nicotine equivalents in spot urine , 2-cyanoethylmercapturic acid

    Time frame: 0-18 months

  14. SAFETY (ADVERSE OUTCOMES)

    Independent DSMB will evaluate the outcomes

    Time frame: 0-18 months

  15. Change in self reported product use

    Time frame: 0-18 months

  16. Change in quality of life

    EQ5D-5L

    Time frame: 0-18 months

  17. Cost/effectiveness analysis

    Time frame: 0-18 months

  18. Subgroup analysis (AGE/SEX/CO-MORBIDITIES)

    Time frame: 1-18 months

07

Study locations

1 of 1 sites recruiting
  • National Institute of Cardiology
    Warsaw, 04-628, Poland
    Recruiting
    • Cezary Kępka, MD PhD · Contactckepka@ikard.pl
    • Cezary Kępka, MD PhD · Principal investigator
    • Mariusz Kruk, MD PhD · Principal investigator
    • Marcin Demkow, MD PhD · Sub investigator
08

References and documents

Publications

  • Biondi-Zoccai G, Sciarretta S, Bullen C, Nocella C, Violi F, Loffredo L, Pignatelli P, Perri L, Peruzzi M, Marullo AGM, De Falco E, Chimenti I, Cammisotto V, Valenti V, Coluzzi F, Cavarretta E, Carrizzo A, Prati F, Carnevale R, Frati G. Acute Effects of Heat-Not-Burn, Electronic Vaping, and Traditional Tobacco Combustion Cigarettes: The Sapienza University of Rome-Vascular Assessment of Proatherosclerotic Effects of Smoking ( SUR - VAPES ) 2 Randomized Trial. J Am Heart Assoc. 2019 Mar 19;8(6):e010455. doi: 10.1161/JAHA.118.010455. PubMed 30879375 ↗
  • Ikonomidis I, Vlastos D, Kostelli G, Kourea K, Katogiannis K, Tsoumani M, Parissis J, Andreadou I, Alexopoulos D. Differential effects of heat-not-burn and conventional cigarettes on coronary flow, myocardial and vascular function. Sci Rep. 2021 Jun 3;11(1):11808. doi: 10.1038/s41598-021-91245-9. PubMed 34083663 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2025, 34 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 34 months is close to that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2022
First posted
Dec 21, 2022
StartActual
Feb 9, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Dec 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05660798
Lead sponsor
National Institute of Cardiology, Warsaw, Poland
Collaborators
PMPSA
Responsible party
Sponsor
First posted
Dec 21, 2022
Start date
Feb 9, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Dec 19, 2024

Study contacts

Cezary Kepka, ND PhD
Contact
ckepka@ikard.pl
+48223434150
Mariusz Kruk, MD PhD
Contact
mkruk@ikard.pl
+48223434342

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion